• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The European Journal of Neuroscience >Post hoc analysis of the Exenatide-PD trial—Factors that predict response
【24h】

Post hoc analysis of the Exenatide-PD trial—Factors that predict response

机译：exenatide-PD试验因素的后HOC分析预测响应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

ABSTRACT: Exenatide, a glucagon-like peptide-1 agonist and a licensed treatment for Type 2 diabetes significantly reduced deterioration in motor symptoms in patients with Parkinson's disease in a randomized, placebo-controlled trial. In addition, there were trends favouring the exenatide group in assessments of nonmotor symptoms, cognition, and quality of life. The aim of this exploratory post hoc analysis was to generate new hypotheses regarding (a) whether candidate baseline factors might predict the magnitude of response to exenatide; and (b) whether the beneficial effects of exenatide reported for the overall population are consistent in various subgroups of patients. Univariate and multivariate analyses were conducted to determine possible predictors of motor response to exenatide in this cohort. Potential treatment by subgroup interactions for changes in; motor severity, nonmotor symptoms, cognition, and quality of life after 48-weeks treatment with exenatide were evaluated among post hoc subgroups defined by age, motor phenotype, disease duration, disease severity, body mass index (BMI), and insulin resistance. In the subgroup analyses, exenatide once-weekly was associated with broadly improved outcome measures assessing motor severity, nonmotor symptoms, cognition, and quality of life across all subgroups, however, tremor-dominant phenotype and lower Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part-2 scores predicted greatest motor response to exenatide and there was an indication that patients with older age of onset and disease duration over 10 years responded less well. While patients with a range of demographic and clinical factors can potentially benefit from exenatide once-weekly, these data support an emphasis towards recruiting patients at earlier disease in future planned clinical trials of gluacagon-like peptide-1 (GLP-1) receptor agonists in Parkinson's disease (PD).
机译：摘要：Exenatide，胰高血糖素的肽-1激动剂和2型糖尿病的许可治疗显着降低了帕金森病在随机安慰剂对照试验中帕金森病的患者症状的恶化。此外，还有趋势赞成eNEnatide组，以评估非等症状，认知和生活质量。该探索性后HOC分析的目的是产生关于（a）候选基线因素是否可能预测对艾塞司的响应程度的新假设; （b）艾塞司是否报告的整体人群的有益效果在患者的各种亚组中是一致的。进行单变量和多变量分析，以确定该队列中的电机反应的可能预测因子。子组相互作用的潜在处理;在由年龄，运动表型，疾病持续时间，疾病严重程度，体重指数（BMI）和胰岛素抵抗的情况下评估48周治疗exenatide治疗后48周的运动严重程度，非热源症状，认知和生活质量。在亚组分析中，艾塞纳西亚含量持续与广泛改善的结果测量有关，这些结果措施评估所有亚组的运动严重程度，非运动症状，认知和生活质量，然而，震颤显性表型和较低的运动障碍社会 - 赞助统一的修订帕金森的疾病评级规模（MDS-UPDRS）Part-2分数预测艾塞司的最大电机反应，迹象表明，年龄较大的发病和疾病持续时间超过10年的患者应对较少。虽然具有一系列人口统计和临床因素的患者可能会受益于每周艾塞司，但这些数据支持强调在未来血糖肽-1（GLP-1）受体激动剂的未来计划临床试验中招募早期疾病的患者帕金森病（PD）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号